# Antimicrobial Activity of Acidifying Hyaluronic Acid–Starch Microfiber Dressings Against Clinical Isolates from Chronic Wounds

**Authors:** Ivana Stará, Petra Moťková, Markéta Vydržalová, Marcela Pejchalová, Ladislav Burgert, Radim Hrdina, Marek Bouška, Martin Adam, Karel Královec, Iveta Brožková

PMC · DOI: 10.3390/jfb17020058 · 2026-01-23

## TL;DR

This paper shows that new hyaluronic acid-starch dressings with acidifying agents can fight microbes in chronic wounds and are safe for cells.

## Contribution

The novelty is the development of HA–Starch microfiber dressings with acidifying agents that show antimicrobial efficacy against clinical isolates.

## Key findings

- The dressings showed significant antimicrobial activity against multidrug-resistant clinical isolates.
- Scanning electron microscopy confirmed uniform microfiber morphology and elemental composition.
- Cytotoxicity tests indicated the materials are safe for potential wound care applications.

## Abstract

Hyaluronic acid (HA) is a natural biopolymer widely used in wound dressings for its supportive role in the healing process. In this study, we investigated the occurrence of microorganisms in chronic wounds and evaluated the antimicrobial activity of newly synthesized HA–Starch-based materials enriched with acidifying agents. Microbial isolates obtained from chronic wounds were tested for susceptibility using the agar diffusion method. The prepared materials exhibited significant antimicrobial activity against both reference strains and multidrug-resistant clinical isolates. Further characterization by scanning electron microscopy and elemental analysis confirmed uniform microfiber morphology and the expected elemental composition of the fibers. Cytotoxicity assessments performed using the xCELLigence system demonstrated the potential safety of developed materials. Overall, the results indicate that HA–Starch-based materials containing acidifying compounds exhibit strong in vitro antimicrobial activity against chronic-wound isolates, supporting their potential for further evaluation in wound care applications.

## Full-text entities

- **Genes:** CAT (catalase) [NCBI Gene 847]
- **Diseases:** Foot (MESH:D005530), infected (MESH:D007239), Ulcers (MESH:D014456), wound infections (MESH:D014946), Cytotoxicity (MESH:D064420), Pressure (MESH:D003668), Diabetic Foot Ulcers (MESH:D017719), abrasions (MESH:D065306), Fournier's gangrene (MESH:D018934), Chronic (MESH:D002908), breast adenocarcinoma (MESH:D001943), M. morganii (MESH:C566367), Gram-negative infections (MESH:D016905), diabetes (MESH:D003920), venous insufficiency ulcer (MESH:D014689), necrotizing fasciitis (MESH:D019115), Chronic wounds (MESH:D014947), Leg Ulcers (MESH:D007871), inflammation (MESH:D007249), Dehiscence (MESH:D013529), skin (MESH:D012871), Leg (MESH:D010264), osteoarthritis (MESH:D010003)
- **Chemicals:** linezolid (MESH:D000069349), salicylate (MESH:D012459), rifampicin (MESH:D012293), N-acetyl-D-glucosamine (MESH:D000117), saccharide (MESH:D002241), Starch (MESH:D013213), cefotaxime (MESH:D002439), HA-Starch (-), Na (MESH:D012964), tetracycline (MESH:D013752), penicillin (MESH:D010406), charcoal (MESH:D002606), nitrofurantoin (MESH:D009582), D-glucuronic acid (MESH:D020723), sodium salicylate (MESH:D012980), glycosaminoglycan (MESH:D006025), cefuroxime (MESH:D002444), aztreonam (MESH:D001398), polyamide 6 (MESH:C009916), H (MESH:D006859), chloramphenicol (MESH:D002701), DMSO (MESH:D004121), CO2 (MESH:D002245), ampicillin (MESH:D000667), cefadroxil (MESH:D002434), sulfamethoxazole-trimethoprim (MESH:D015662), doripenem (MESH:D000077726), mupirocin (MESH:D016712), N (MESH:D009584), polysaccharide (MESH:D011134), C (MESH:D002244), polymer (MESH:D011108), ester (MESH:D004952), agar (MESH:D000362), ciprofloxacin (MESH:D002939), polyamide (MESH:D009757), cefoxitin (MESH:D002440), O (MESH:D010100), SA (MESH:D020156), fiber (MESH:D004043), MHA (MESH:C069357), acids (MESH:D000143), gentamicin (MESH:D005839), 2-propanol (MESH:D019840), BS (MESH:D001895), HA (MESH:D006820), amoxicillin (MESH:D000658), erythromycin (MESH:D004917), clindamycin (MESH:D002981), ticarcillin (MESH:D013982), ASA (MESH:D001241), E (MESH:D004540), H2O (MESH:D014867), levofloxacin (MESH:D064704), vancomycin (MESH:D014640)
- **Species:** Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Staphylococcus aureus (species) [taxon 1280], Staphylococcus epidermidis (species) [taxon 1282], Homo sapiens (human, species) [taxon 9606], Proteus mirabilis (species) [taxon 584], Hepatovirus A (no rank) [taxon 12092], Corynebacterium striatum (species) [taxon 43770], Neisseria flavescens (species) [taxon 484], Staphylococcus haemolyticus (species) [taxon 1283], Providencia stuartii (species) [taxon 588], Finegoldia magna (species) [taxon 1260], Enterobacteriaceae (enterobacteria, family) [taxon 543], Rothia mucilaginosa (species) [taxon 43675], Streptococcus agalactiae (species) [taxon 1311], Morganella morganii (species) [taxon 582], PX clade (clade) [taxon 569578], Pseudomonas aeruginosa (species) [taxon 287], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Streptococcus sp. 'group A' (species) [taxon 36470], Klebsiella pneumoniae (species) [taxon 573], Candida albicans (species) [taxon 5476], Escherichia coli (E. coli, species) [taxon 562], Rothia dentocariosa (species) [taxon 2047], Pseudomonas sp. S (species) [taxon 413904], Enterococcus faecalis (species) [taxon 1351], Staphylococcus schleiferi (species) [taxon 1295]
- **Cell lines:** ATCC 10231 — Homo sapiens (Human), Hereditary hemorrhagic telangiectasia, Transformed cell line (CVCL_W904), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941604/full.md

---
Source: https://tomesphere.com/paper/PMC12941604